Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ista drops 31% and looks to EAST as Remura goes WEST in late-stage dry eye trial

This article was originally published in Scrip

Executive Summary

Ista Pharmaceuticals has suffered a setback in its plans for its latest extension of its bromfenac sodium franchise. It revealed that its lower concentration of bromfenac, Remura (bromfenac ophthalmic), missed the co-primary endpoints of improving one sign and one symptom of dry eye disease at day 42 versus placebo in the first of two Phase III studies. Ista shares fell $2.23, or 31%, to $4.97 in late trading on 29 July.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts